Leadership
In an exclusive interview, Generics Bulletin spoke to a trio of experts who argue that biosimilar cell and gene therapies are technically within reach but demand unprecedented regulatory clarity, manufacturing evolution and economic alignment before they become reality.
As Alvotech continues to reorganize its senior team with the promotion of chief scientific officer Joseph McClellan to chief operating officer, multiple other firms – including Hikma, Hyloris, CNX and Cingulate – have also announced executive updates.
Axplora made waves with a recent announcement that the API specialist’s total investments for 2025 would exceed €100m. Anant Barbadikar, co-president of the firm’s PharmaZell business unit, explains how the firm’s strategy is evolving and why he believes the future of pharma remains small-molecule.
In the wake of recent FDA guidance on streamlining the registration pathway for biosimilars, Organon’s head of US biosimilars, Jon Martin, talks to Generics Bulletin about how the company is re-evaluating the market landscape.
Hikma has started searching for a new Injectables head after Bill Larkins stepped down, at the same time as the firm has begun a reorganization of its R&D operations. Meanwhile, Stada has named a new head of Germany and Viatris has promoted a key executive in Europe.
In an exclusive interview with Generics Bulletin, Celltrion USA executives Tom Nusbickel and Juby Jacob-Nara discuss recent biosimilar launches, streamlining, moves into more innovative areas, and how Celltrion’s recent commitment to US manufacturing shows that the firm is “in it for the long run.”
With another regulator now considering the removal of clinical efficacy trials for biosimilars, BioPharmaSpec’s technical director Richard Easton paints the picture of data-powered biosimilarity assessment.
Cipla’s global CEO and MD Umang Vohra is moving on handing over the baton to global COO, Achin Gupta. Vohra talks about his innings, where he sees Cipla in 2030 and the impact of the latest FDA action that aims to make biosimilar development faster and less costly.
Organon is looking for a new CEO after an internal investigation uncovered “improper wholesaler sales practices” relating to its Nexplanon implant. The firm will not revise any previously issued financial statements, despite saying that the tactics helped meet revenue expectations.
‘Generics Manufacturers Are Central To Our Mission’ – International Health Partners On Collaboration
With the work undertaken by non-governmental organization International Health Partners to provide access to vital medicines more important than ever, the organization talks to Generics Bulletin about how its work is growing and how companies in the off-patent sector can get involved.
Polpharma has disclosed a successor to current CEO Markus Sieger. Meanwhile, Alvotech has announced a trio of appointments to its BD and commercial operations team; Sun Pharma has appointed a North America head of corporate affairs; and Biocon Biologics has named a fresh head of corporate finance.
As the US biosimilars market enters its second decade, Cencora’s director of biosimilar commercialization Dennis Nelson talks to Generics Bulletin about the progress made so far, as well as fresh regulatory and commercial developments on the horizon.
Watch now as Adalvo CEO Anil Okay shares with Citeline his perspectives on the rapidly-growing European B2B’s recent acquisition by private equity firm EQT. Find out what it means for the business, and how it may reflect wider pharma trends, in this insightful video interview.
Polpharma CEO Markus Sieger has announced that he will be stepping down from the role at the end of this year, while his duties as president of Medicines for Europe are also set to pass to a successor.
In a detailed interview, Aurobindo’s European CEO Venugopalan Muralidharan – Murali – explains how the firm is increasingly focusing on complex products such as injectables and biosimilars, as well as eyeing upcoming opportunities such as GLP-1s and ADCs, while also remaining open to potential M&A.
Months after his departure from Stada and Medicines for Europe, Stephan Eder has been named as the new CEO of Pharmanovia. Meanwhile, CNX, Adalvo, Mallinckrodt and EuroAPI have also announced fresh leadership changes.
Generics Bulletin editor Dave Wallace talks to John Murphy III, president and CEO of the US Association for Accessible Medicines, about the association’s latest annual savings report and key topics affecting the US off-patent market.
After launching two biosimilars and acquiring another leading marketed product in a little over a year, Accord Biopharma has made a major push into US biosimilars. Accord US president Chrys Kokino explains to Generics Bulletin how the firm is seeking to become the market leader.
Launching its new manufacturing site in New Jersey will help bring Biocon Limited closer to the US market while also bolstering vertical integration, explains the firm’s managing director and CEO Siddharth Mittal in an exclusive interview about the new development.
In the second part of Generics Bulletin’s interview with Róbert Wessman, the Alvotech founder, chairman and CEO discusses global moves towards biosimilar streamlining – as well as talking PBMs, price negotiation, US trade tariffs and the push towards reshoring manufacturing.